ENOVNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Enovis CORP
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 6, 2026
$19.87+0.28 (+1.43%)
Close on Oct 19, 2026
- Market cap
- $1.14B
- P/E (TTM)
- –
- Dividend yield
- –
Enovis CORP revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reconstructive | $1.16B | $1.14B | $1.11B | $1.09B | $1.07B | $1.04B | $1.01B | $908.38M | $824.64M | $732.26M | $630.42M | $603.88M | 50.6% | +9.1% |
| Prevention & Recovery: | – | – | $1.14B | $1.14B | $1.12B | $1.11B | $1.10B | $1.09B | $1.09B | $1.09B | $1.08B | $1.06B | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Enovis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.